This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Lubet RA , Townsend R , Clapper ML , Juliana MM , Steele VE , McCormick DL , Grubbs CJ
5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target?
Cancer Prev Res (Phila). 2016 May 5;9(7) :616-23
PMID: 27150634 PMCID: PMC4930704 URL: http://www.ncbi.nlm.nih.gov/pubmed/27150634
AbstractThe preventive efficacy of the triterpenoid 5MeCDDO was tested in two models of mammary cancer, the Min model of intestinal cancer, and a chemically-induced model of head and neck cancer. In one model of mammary cancer, female Sprague-Dawley rats were administered MNU at 50 days of age, and 5MeCDDO (27 ppm) was administered in the diet beginning five days later for the duration of the study; 5MeCDDO was ineffective. In contrast, in a model examining initiation of mammary cancers by the pro-carcinogen dimethyl-benzanthracene (DMBA), 5, 6-benzoflavone (500 ppm, an Ah receptor agonist) or 5MeCDDO (27 or 2.7 ppm) decreased tumor multiplicity by 90, 80 and 50%, respectively. This anti-initiating effect which is presumably mediated by altered metabolic activation parallels our observation that 5MeCDDO induced proteins of various ARE related Phase II drug-metabolizing enzymes [e.g., GST Pi, AKR 7A3 (aflatoxicol), epoxide hydrolase, and quinone reductase] in the liver. 5MeCDDO tested in the 4-nitroquinoline-l-oxide (4-NQO) head and neck cancer model failed to decrease tumor incidence or invasiveness. In the Min mouse model of intestinal cancer, a high dose of 5MeCDDO (80 ppm) was weakly effective in reducing adenoma multiplicity [approximately 30% (P<0.05)]; however, a lower dose was totally ineffective. These findings question whether measuring increased levels of certain ARE related genes (e.g., quinone reductase, GST Pi), indicating decreased carcinogen activation are sufficient to imply general chemopreventive efficacy of a given agent or mixture.
NotesLubet, Ronald A Townsend, Reid Clapper, Margie L Juliana, M Margaret Steele, Vernon E McCormick, David L Grubbs, Clinton J N01 CN043301/CN/NCI NIH HHS/United States Cancer Prev Res (Phila). 2016 May 5. pii: canprevres.0294.2015.